Tore Curstedt awarded with the Grand Silver Medal 2017

Published 2017-09-14 14:27. Updated 2017-09-14 14:30Denna sida på svenska

Associate Professor Tore Curstedt at the Department of Molecular Medicine and Surgery at Karolinska Institutet has been awarded the Grand Silver Medal for the work he and his colleague Bengt Robertson, who died in 2008, have done on their innovative treatment for preterm babies with respiratory distress syndrome (RDS). RDS has been the leading cause of death among preterm babies for decades. 

It has been known since the 1950s that premature babies die due to the lack of surfactant, the substance which surrounds the inside of the lung alveoli. Attempts to synthesize the substance started in the 1960s, but these failed. However, when Pathologist Bengt Robertson and Clinical Chemist Tore Curstedt joined forces, they managed to extract the active ingredients from porcine lungs and develop a drug, Curosurf, which is used in more than 90 countries and is estimated to have saved more than half a million preterm babies. 

Tore Curstedt has together with a colleague also developed a synthetic surfactant which is in clinical trials in United States and Europe. Unlike Curosurf the synthetic drug can be produced in large amounts and enables future treatment of adults suffering of lung diseases associated with inactive surfactant. He has received the Stockholm County Council Prize for Breakthrough in Clinical Research and His Majesty The King´s Gold Medal of the 12th size on a blue ribbon.

The Grand Silver Medal 2017 from Karolinska Institutet is awarded to Tore Curstedt and Marc Bygdeman in special recognition of the outstanding contributions they have made to medical research and Karolinska Institutet.
Award